



Diclegis[®] (doxylamine succinate/pyridoxine) – First-time generic

- On June 21, 2019, [Teva launched](#) an [AB-rated](#) generic version and [Analog Pharma launched](#) an authorized generic version of Duchesnay's [Diclegis \(doxylamine succinate/pyridoxine\)](#) delayed-release tablet 10 mg/10 mg.
 - Par received FDA approval of an [AB-rated](#) generic version of Diclegis on December 6, 2017. Launch plans for this generic are pending.
- Diclegis is approved for the treatment of nausea and vomiting of pregnancy in women who do not respond to conservative management.
- Doxylamine succinate/pyridoxine is also available as a brand delayed-release tablet 20 mg/20 mg ([Bonjesta[®]](#)), and carries the same indication as Diclegis.



OptumRx[®] specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum[®] company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum[®] trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews[®] is published by the OptumRx Clinical Services Department.

©2019 Optum, Inc. All rights reserved.